2018 American Transplant Congress
C1q-Binding Donor-Specific Anti-HLA Antibodies for Clinical Decision Making in Kidney Recipients with Antibody-Mediated Rejection Receiving Standard of Care Treatment
One of the major issues in the clinical management of kidney recipients with ABMR is the lack of early and reliable markers that surrogate long-term…2018 American Transplant Congress
An In Vitro Model of Human Antibody-Mediated Rejection Depicts Key Role for NK Cells
AIM: Antibody-mediated rejection (ABMR) is the leading cause of kidney allograft loss but its immune mechanisms are incompletely understood. We sought to examine key interactions…2018 American Transplant Congress
Flow DSA-XM: Better Crossmatch or Just Different Problems?
Surgery, VCUHealth Systems, Richmond, VA.
Background. Despite the positive impact of flow crossmatching(FCXM) upon alloantibody detection, its inability to distinguish anti-Class I from Class II or non-HLA from HLA-antibodies remain…2018 American Transplant Congress
Time in Therapeutic Range Predicts DSA Development and Acute Rejection in Kidney Recipients with High Tacrolimus Coefficient of Variation
University of Colorado, Aurora, CO.
High tacrolimus trough coefficient of variation (TAC CV) has been associated with an increased risk of de novo donor-specific antibody (dnDSA) and acute rejection (AR).…2018 American Transplant Congress
Subclass Distribution of DSA Analyzed by Mass Spectrometry Predicts the Risk of Humoral Rejection
Background :DSA occurrence after kidney transplant is a main risk factor for humoral rejection and graft loss, however graft outcomes after DSA detection is very…2018 American Transplant Congress
Heart Transplant across Low or Moderate Level Donor-Specific Antibodies Have Acceptable Outcome
Cedars Sinai Medical Center, Los Angeles.
Purpose: The presence of pre-transplant donor specific antibodies (DSA) can reduce the likelihood of a patient (pt) obtaining a compatible donor heart. The proportion of…2018 American Transplant Congress
Influence of Trough Level in Tacrolimus on the Appearance Rate of De Novo Donor Specific Antibody (dnDSA) under Low Dose-Based Tacrolimus Protocol during 7 Years Follow-Up after Renal Transplantation
Background. Tacrolimus low trough protocol has been adopted at our institution since 2000.The purpose in this study is to investigate the relationship between maintenance trough…2018 American Transplant Congress
Shared HLA Specificities between the Blood and Transplant Donor Increases the Risk of De Novo DSA Development Following Blood Transfusion in Transplant Recipients
Introduction: Blood transfusions post-transplant have been shown to be associated with the development of de novo DSA and inferior allograft outcomes. The mechanisms behind this…2018 American Transplant Congress
Clinical Significance of Microvascular Inflammation in the Absence of Anti-HLA DSA in Kidney Transplantation
University of Wisconsin, Madison.
Background: It is not uncommon to have biopsy specimens meeting Banff glomerulitis (g) plus peritubular capillaritis (ptc) and/or c4d scores that meet criteria for antibody…2018 American Transplant Congress
What Threshold MFI is the Luminex 1:8 Dilution the Poor Man's C1q for Patients Awaiting Heart Transplant?
Cedars Sinai Medical Center, Los Angeles.
Purpose: Heart transplant candidates are evaluated for anti-HLA antibodies by Luminex single-antigen bead testing to avoid donors that may harbor antigens that these antibodies are…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 47
- Next Page »